HomeCompareIOBCF vs MRK

IOBCF vs MRK: Dividend Comparison 2026

IOBCF yields 1.84% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IOBCF wins by $45.29M in total portfolio value· pulled ahead in Year 3
10 years
IOBCF
IOBCF
● Live price
1.84%
Share price
$15.00
Annual div
$0.28
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.35M
Annual income
$41,068,608.41
Full IOBCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — IOBCF vs MRK

📍 IOBCF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIOBCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IOBCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IOBCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IOBCF
Annual income on $10K today (after 15% tax)
$156.68/yr
After 10yr DRIP, annual income (after tax)
$34,908,317.15/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, IOBCF beats the other by $34,899,988.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IOBCF + MRK for your $10,000?

IOBCF: 50%MRK: 50%
100% MRK50/50100% IOBCF
Portfolio after 10yr
$22.70M
Annual income
$20,539,203.28/yr
Blended yield
90.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IOBCF
No analyst data
Altman Z
2.4
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IOBCF buys
0
MRK buys
0
No recent congressional trades found for IOBCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIOBCFMRK
Forward yield1.84%2.76%
Annual dividend / share$0.28$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$45.35M$56.8K
Annual income after 10y$41,068,608.41$9,798.13
Total dividends collected$44.99M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IOBCF vs MRK ($10,000, DRIP)

YearIOBCF PortfolioIOBCF Income/yrMRK PortfolioMRK Income/yrGap
1$11,069$368.67$11,206$366.19$137.00MRK
2$12,606$762.74$12,650$502.35$44.00MRK
3← crossover$15,112$1,623.72$14,407$694.19+$705.00IOBCF
4$19,809$3,638.35$16,585$967.82+$3.2KIOBCF
5$30,109$8,913.99$19,342$1,363.89+$10.8KIOBCF
6$57,543$25,325.84$22,913$1,947.19+$34.6KIOBCF
7$152,040$90,469.27$27,662$2,823.89+$124.4KIOBCF
8$609,485$446,801.92$34,159$4,173.35+$575.3KIOBCF
9$4,000,001$3,347,852.94$43,337$6,308.80+$3.96MIOBCF
10$45,348,610$41,068,608.41$56,776$9,798.13+$45.29MIOBCF

IOBCF vs MRK: Complete Analysis 2026

IOBCFStock

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Full IOBCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this IOBCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IOBCF vs SCHDIOBCF vs JEPIIOBCF vs OIOBCF vs KOIOBCF vs MAINIOBCF vs JNJIOBCF vs ABBVIOBCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.